CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Adavosertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03253679
NCT03253679Phase 2Completed
CompareCT.gov

A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification

National Cancer Institute (NCI)·interventional·Posted Aug 18, 2017·Updated Oct 17, 2023

In Brief

A Phase 2 clinical trial evaluating Adavosertib for Advanced Malignant Solid Neoplasm and Refractory Malignant Solid Neoplasm. Completed, enrolled 31 participants across 9 sites.

Detailed Summary

This phase II trial studies how well AZD1775 works in treating patients with solid tumors with CCNE1 amplification that have spread to other places in the body (advanced) and do not respond to treatment (refractory). AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 18, 2017
Enrollment StartJan 16, 2019
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 8.9 years ago

Interventions

Adavosertibdrug

Given PO